SETDB1 and neoplasm: Recently, the utility of SETDB1 as a potent therapeutic target in combination with immune checkpoint blockade was highlighted based on the finding that SETDB1 inactivation generated TE-encoded antigens to boost tumor immunogenicity (43,45).